FluGen announced today it has begun a Phase I clinical trial of its universal influenza vaccine called RedeeFlu.

“The initiation of this first-in-man study is an important milestone achieved through the research and development efforts of the FluGen team and our collaborators,” President and CEO Paul Radspinner said in a statement. “We believe that RedeeFlu could be the first influenza vaccine to show robust protection from drifted or mismatched flu strains.”

According to a release, the goal of the trial is to evaluate the safety of the vaccine as well as the antibody and T-cell responses induced by the vaccine in 96 healthy adults ages 18-49.